Skip to content

Subthreshold early white-matter hyperintensity increase predicts accelerated hippocampal and whole-brain atrophy in anti-amyloid-β immunotherapy

Aug 2026 · Journal of Alzheimer's Disease · Vol 113, pp. 1099 - 1109 · 0 citations · 32 references
Medicine

TL;DR

A transient WMH surge within the first 60 days of therapy mirrors the known time course of amyloid-related imaging abnormalities and independently predicts accelerated long-term hippocampal and whole-brain atrophy, highlighting its potential as an early prognostic imaging marker.

Abstract

Background Anti-amyloid-β (anti-Aβ) therapy slows cognitive decline but paradoxically accelerates whole-brain gray matter atrophy, complicating outcome prediction. Objective To identify early imaging markers that predict long-term prognoses. Methods This longitudinal cohort study prospectively enrolled participants with early Alzheimer's disease, initiating anti-Aβ therapy. We performed automated T1-weighted MRI volumetric analysis of the whole-brain gray matter, hippocampus, and white matter hyperintensities (WMH). Temporal dynamics were characterized using piecewise linear regression, and predictive utility was assessed using multivariate linear regression analyses. Results Twenty-two participants (74 ± 11 years; 14 women) were followed for 376 ± 146 days. Significant volume changes occurred in all regions (p < 0.01). No overt amyloid-related edema was detected, and hemorrhagic events were mild to moderate. Piecewise regression revealed an initial WMH surge that decelerated after 60 days (β=-0.19 [95%CI: −0.33, −0.042], p = 0.01), whereas gray matter regions showed linear volume decline. Early subthreshold WMH expansion predicted long-term atrophy independent of baseline covariates (age, sex, amyloid burden, mini–mental state examination score, drug, and hemorrhagic events) in the hippocampus (β=-0.058 [95%CI: −0.092, −0.025], p = 0.003), and whole-brain gray matter (β=-0.033 [95%CI: −0.065, −0.002], p = 0.04). Early whole-brain gray matter atrophy correlated with the WMH surge (β=-0.53 [95%CI: −0.69, −0.38], p < 0.001) and predicted long-term hippocampal atrophy (β=0.098 [95%CI: 0.038, 0.16], p = 0.004). Conclusions A transient WMH surge within the first 60 days of therapy mirrors the known time course of amyloid-related imaging abnormalities. Along with concurrent early whole-brain volume loss, this surge independently predicts accelerated long-term hippocampal and whole-brain atrophy, highlighting its potential as an early prognostic imaging marker.

View source

Similar papers

Open access Aug 2026

Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer’s disease

In this large longitudinal sample of asymptomatic individuals, the Aβ-dominant biomarker component showed the strongest association with longitudinal GM atrophy and cognitive decline, beyond the effects of tau pathophysiology and neuroaxonal injury.

W. Pelkmans, R. Cacciaglia, Michalis Kassinopoulos et al. · 0 citations
Open access Jul 2026

Anti‐amyloid immunotherapy and brain volume trajectories in early‐onset versus late‐onset Alzheimer's disease

Accelerated brain volume loss has been observed following trials of anti‐amyloid beta immunotherapy (AAT); however, there is limited understanding of this paradoxical phenomenon in early‐onset Alzheimer's disease (EOAD) versus late‐onset Alzheimer's disease (LOAD).

R. Mehta, Methasit Jaisa-aad, Camila Vieira Ligo Teixeira et al. · 0 citations
Open access Aug 2026

Cerebral amyloid-β burden and white matter injury: associations, clues for underlying mechanisms, and implication on cognitive trajectory after lecanemab therapy.

The interplay of Aβ with white matter integrity contributes to cognitive decline in the context of Alzheimer's disease, with greater cognitive improvement observed among those with smaller WMH reductions.

Ke Shi, Xin-Yu Luo, Tong-Tong Liu et al. · 0 citations
Open access Sep 2026

Longitudinal patterns of regional cerebral blood flow during anti-amyloid therapy in mild cognitive impairment: a pilot ASL MRI case series

The observed rCBF trajectories demonstrate region-specific and time-dependent perfusion changes over the treatment period and should be interpreted cautiously as exploratory and hypothesis-generating rather than evidence of treatment efficacy.

Eva Y. W. Cheung, Y. Shea, P. Chiu et al. · 0 citations
Open access Sep 2026

Spatiotemporal Atrophy Subtypes in Alzheimer's Disease: Neurodegenerative-Vascular Associations and Potential Prognostic Value.

Bomarker-confirmed AD comprised internally reproducible atrophy trajectories with distinct cognitive, vascular, and molecular profiles and may complement fluid biomarkers and conventional volumetry for patient stratification and prognosis.

Chen-Hui Mao, Yu-Yue Qiu, Bo Li et al. · 0 citations
Open access Aug 2026

Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers

Alzheimer’s disease (AD) develops silently for years before symptoms emerge, making early identification of at-risk individuals essential for prevention trials and early intervention. We tested whether combining neurophysiological, imaging, and blood biomarkers improves prediction of progression to mild cognitive impai...

Jonathan Gallego-Rudolf, A. I. Wiesman, Y. Yakoub et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.